Advertising
COMMENT
Expectations for 2022. Markets up over 20% this year. Third year of straight double digit gains. Hopefully 2022 will return to normal. Supply chains will resolve probably in Q3 or Q4, inventories will be replenished, and growth will deaccelerate from very high rates off the bottom.
Unknown
COMMENT
Market challenges. The Fed has its hands full. CPI hitting 4.9% in November, 30-year highs. Unemployment levels at 4.2%. Going forward, have to look at pricing power. Brand strength is vital to maintaining margins and market share. Key to strong businesses is being able to raise prices without losing market share. For example, some global consumer products companies, such as UL, may lose pricing power because they're up against private label penetration in key categories such as food or home care. This is a red flag for next year if you think prices are going higher, which could motivate people to substitute private labels for brands names.
Unknown
COMMENT
Sector focus. He doesn't advise from a sector point of view. He runs a concentrated portfolio, with 35-45 names. Bottom up approach, developing a thesis, with a target price.
Unknown
COMMENT
Key to 2022. Brand names, with higher margin businesses and sustainable business models are key. Short term, 2022, we'll see higher prices from "transitory" inflation. In 2020, things were fine, and then the world stopped working. Easy to stop, but harder to bring the world back up to speed. So we're seeing shortages and backlogs. It'll take 6-12 month to resolve, you have to be patient.
Unknown
DON'T BUY
Well off highs. Missed last earnings forecast in November. Margins were weak. Market's worried about continued fragmentation of e-commerce in China. Management missteps, Chinese political situation is dicey at best, Jack Ma is in the penalty box. Stay away. He owns AMZN, as it's well positioned for the future.
0
HOLD
Well positioned for the future. His position in the e-commerce space instead of BABA.
specialty stores
HOLD
Electronic medical record software. Expectations are very high. Still in growth mode, so not profitable. Street's target is $11, with 60% growth expected next year. Overall, healthcare IT is an interesting space. Lots of competition. A hold. More research required before buying.
Healthcare